abrdn Healthcare Investors (NYSE:HQH) Stock Crosses Below 50 Day Moving Average – Time to Sell?

abrdn Healthcare Investors (NYSE:HQH)’s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $19.48 and traded as low as $19.40. abrdn Healthcare Investors shares last traded at $19.5230, with a volume of 178,530 shares.

abrdn Healthcare Investors Price Performance

The company has a 50-day moving average price of $19.48 and a 200-day moving average price of $19.13.

abrdn Healthcare Investors Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Thursday, May 21st will be given a $0.61 dividend. This represents a $2.44 annualized dividend and a dividend yield of 12.5%. The ex-dividend date is Thursday, May 21st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in HQH. Bollard Group LLC bought a new position in shares of abrdn Healthcare Investors in the 1st quarter worth $25,000. Geneos Wealth Management Inc. boosted its position in shares of abrdn Healthcare Investors by 9,232.3% in the 2nd quarter. Geneos Wealth Management Inc. now owns 2,893 shares of the financial services provider’s stock worth $45,000 after purchasing an additional 2,862 shares during the last quarter. Flagship Harbor Advisors LLC bought a new position in shares of abrdn Healthcare Investors in the 4th quarter worth $48,000. Advisory Services Network LLC bought a new position in shares of abrdn Healthcare Investors in the 3rd quarter worth $97,000. Finally, Global Retirement Partners LLC bought a new position in shares of abrdn Healthcare Investors in the 4th quarter worth $106,000. 32.60% of the stock is currently owned by institutional investors.

abrdn Healthcare Investors Company Profile

abrdn Healthcare Investors (NYSE:HQH) is a closed-end management investment company that seeks long-term capital appreciation and current income by investing primarily in equity securities of companies operating in the healthcare sector. The fund’s portfolio generally comprises a diversified mix of domestic and international healthcare issuers, spanning pharmaceuticals, biotechnology, medical devices, healthcare services, and related industries.

The fund employs a fundamental, research-driven approach to select investments, focusing on companies with strong balance sheets, innovative product pipelines and the potential for sustainable revenue growth.